CROs Might Be the Engine That Keeps Preclinical Research Moving During COVID-19
BioCentury
The COVID-19 shutdown might see a large swing to CROs, which allow organizations to minimize the risk to both their workforce and their preclinical pipelines by investing in external R&D.
